Adults with overweight or obesity who received once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and ...

Approximately 15 million Americans are on a GPL-1 or better known as Ozempic, Wegovy and Zepbound but there will be upcoming ...

CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...

That is according to the findings of a study presented on Friday at the European Academy of Neurology congress. The pilot ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side ...

In a move that could reshape how doctors approach both weight and heart health, the American College of Cardiology (ACC) ...

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...